Augtyro

repotrectinib

Approval

ApplicationNDA 218213
Approval dateNov 15, 2023
Approval year2023
SponsorBristol

FDA-approved use

To treat ROS1-positive non-small cell lung cancer

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Augtyro: